Luzhu Biotechnology’s LZ901 Herpes Zoster Vaccine Trial Fully Enrolls 26,000 Participants
Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a leading manufacturer of human vaccines and therapeutic...
Company
Danaher Corporation to Establish Northern China Headquarters in Beijing’s Changping District
The Changping District People’s Government of Beijing Municipality has entered into a strategic cooperation agreement...
Glorious Med and Illumina Join Forces for Advanced Urinary Tract Infection Detection
Hangzhou-based Glorious Med, a premier company specializing in gene detection for urinary system tumors, has...
CARsgen Therapeutics’ CT041 Shows Promising Results in Advanced Solid Tumors at ASCO GI 2024
China-based CAR-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the presentation of...
Ultrasound Biotechnology Earns FDA Nod for Disposable Endoscopic Ultrasound Probes
Ultrasound Biotechnology, the Shanghai-based wholly owned subsidiary of US firm Ultrasound Wondering, Inc., has announced...
Meinian Onehealth Collaborates with Huawei Cloud and Runda Medical on AI Health Robot
Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044) has entered into a strategic partnership with...
Sinovac Biotech Ltd Dismisses UK Private Equity’s Nominal Share Acquisition Offer
Sinovac Biotech Ltd (NASDAQ: SVA) has released a statement declaring that its board of directors...
Beijing Aosaikang Initiates Phase III Trial for Advanced Gastric Cancer Treatment
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has registered a Phase...
Zhejiang Dian Diagnostics Partners with Gulf Medical University for Middle East Expansion
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a Chinese diagnostics company, has entered into a...
FDA Approves Casgevy, the First CRISPR-Based Gene Editing Therapy for β-Thalassemia
Casgevy (exagamglogene autotemcel), the pioneering gene editing therapy based on CRISPR technology, has received approval...
Shanghai-Based NK CellTech Earns FDA IND Clearance for Non-Genetically Modified NK Cell Therapy
NK CellTech, a Shanghai-based developer of NK cell therapies, has announced that it has received...
USPTO Invalidates Key Seagen-Held Patent in ADC Conjugation Dispute with Daiichi Sankyo
In a surprising turn of events in the ongoing intellectual property dispute, the US Patent...
Bayer Unveils New Operating Model to Drive Profitable Growth Amid Challenges
Facing a challenging business landscape, Germany’s Bayer (ETR: BAYN) has announced a new operating model...
Eisai and Medivir’s Combo Therapy Advances in Liver Cancer with Positive Trial Results
Japanese pharmaceutical company Eisai’s (TYO: 4523) kinase inhibitor Lenvima (Lenvatinib), combined with Swedish partner Medivir’s...
Hansoh Pharmaceutical Advances Schizophrenia Treatment with HS-10509 Clinical Trial Approval
Hansoh Pharmaceutical (HKG: 3692) has announced that it has received approval to commence clinical trials...
Sino Biopharmaceutical Receives NMPA Approval for Generic Revolade Equivalent
Sino Biopharmaceutical Ltd (HKG: 1177), a major player in the Chinese pharmaceutical industry, announced that...
Luye Pharma’s Biosimilar Bevacizumab Gets GMP Certification in Brazil
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that...
Regenxbio’s One-Time Gene Therapy for Wet AMD Shows Promise in Phase II Study
Gene therapy specialist Regenxbio (NASDAQ: RGNX) has announced preliminary results from a Phase II study...
Takeda’s Hyqvia Approved by FDA for Chronic Inflammatory Demyelinating Polyneuropathy
Japanese pharmaceutical company Takeda (TYO: 4502) has received an indication extension approval from the US...
Qilu Pharmaceutical’s Iruplinalkib Gains Additional Indication Approval in China for ALK-Positive NSCLC
The National Medical Products Administration (NMPA) website has indicated that Qilu Pharmaceutical’s Category 1 drug,...